Cargando…
Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
BACKGROUND: Bevacizumab improves progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer patients however currently there are no biomarkers that predict response to this treatment. The aim of this study was to assess if differential protein expression can differenti...
Autores principales: | Martin, Petra, Noonan, Sinead, Mullen, Michael P, Scaife, Caitriona, Tosetto, Miriam, Nolan, Blathnaid, Wynne, Kieran, Hyland, John, Sheahan, Kieran, Elia, Giuliano, O’Donoghue, Diarmuid, Fennelly, David, O’Sullivan, Jacintha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289341/ https://www.ncbi.nlm.nih.gov/pubmed/25428203 http://dx.doi.org/10.1186/1471-2407-14-887 |
Ejemplares similares
-
Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment
por: Noonan, Sinead A., et al.
Publicado: (2018) -
Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer
por: Murphy, Adrian G., et al.
Publicado: (2016) -
Tumour Tissue Microenvironment Can Inhibit Dendritic Cell Maturation in Colorectal Cancer
por: Michielsen, Adriana J., et al.
Publicado: (2011) -
Nuclear oxidative damage correlates with poor survival in colorectal cancer
por: Sheridan, J, et al.
Publicado: (2009) -
Characterising the prognostic potential of HLA-DR during colorectal cancer development
por: Dunne, Margaret R., et al.
Publicado: (2020)